Senate confirms Dr Robert Califf to lead FDA
February 25, 2016Medical Communications Drug pricing, FDA, Robert Califf
The US Senate has confirmed Dr Robert Califf as Commissioner of the Food and Drugs Administration, in an overwhelming 89-4 …
European Commission approves Lilly’s Portrazza for NSCLC
February 24, 2016Research and Development Eli Lilly, Portrazza
The European Commission has approved Eli Lilly’s Portrazza (necitumumab), in combination with gemcitabine and cisplatin chemotherapy, as a first-line treatment …
J&J fined $72 million in talc cancer case
February 24, 2016Research and Development, Sales and Marketing Johnson & Johnson
A Missouri jury has ruled that Johnson & Johnson must pay $72 million to the family of an Alabama woman, …
Janssen says cabotegravir/rilpivirine combo matches three-drug HIV maintenance therapy
February 24, 2016Research and Development Janssen, ViiV
Janssen has announced 32-week data from an ongoing phase IIb study of an HIV regimen comprised of its rilpivirine and …
NeuroVive board selects Erik Kinnman as new CEO
February 23, 2016Mitochondrial medicine specialist NeuroVive Pharmaceutical’s board of directors has selected Erik Kinnman as the company’s new chief executive, from March …
Novo Nordisk says Tresiba reduces hypoglycaemia risk vs Lantus
February 23, 2016Manufacturing and Production, Research and Development Novo Nordisk
Novo Nordisk has announced trial results suggesting that its drug Tresiba (insulin degludec) carries a reduced risk of hypoglycaemia episodes, …
Valeant likely to restate financial results after Philidore review
February 23, 2016Manufacturing and Production, Medical Communications, Sales and Marketing Howard Schiller, Philidore, Valeant
Valeant says it is likely to restate its financial results for the last two years, in the wake of the …
ViiV completes BMS HIV pipeline purchase
February 23, 2016Manufacturing and Production, Medical Communications, Research and Development Bristol-Myers Squibb, GSK, HIV, Pfizer, Shionogi, ViiV
ViiV Healthcare has completed its previously-announced acquisition of Bristol-Myers Squibb’s late-stage HIV R&D assets and its portfolio of preclinical and …
Califf clears key hurdle to FDA top job
February 23, 2016Manufacturing and Production, Medical Communications, Research and Development
Dr Robert Califf, President Obama’s nominee to head up the US Food and Drugs Administration as commissioner, has edged a …
Europe approves Bayer haemophilia drug
February 22, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bayer, haemophilia a
Bayer has received approval from the European Commission for its haemophilia A drug Kovaltry (octocog alfa) in patients of all …
March edition of Pharmafocus live
February 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
The March 2016 edition of Pharmafocus is now live and available to read here.
Amgen and UCB announce positive romosozumab results
February 22, 2016Medical Communications, Research and Development, Sales and Marketing Amgen, Romosozumab, UCB, osteoporosis
Romosozumab development partners Amgen and UCB have announced positive top-line results from a Phase III study of the drug in postmenopausal …
Merck launches infertility programme in Uganda
February 22, 2016Medical Communications, Sales and Marketing Merck Serono
Germany’s Merck has extended its infertility programme ‘Merck More than a Mother’ to Uganda, launching the campaign in a second …
FDA to decide on Sanofi diabetes combo
February 22, 2016Research and Development, Sales and Marketing Lantus, Sanofi
Sanofi will be looking to August for a decision on its new type 2 diabetes combo LixiLan (lixisenatide and Lantus), …
Novartis drug PKC412 gets Breakthrough designation for AML
February 19, 2016Medical Communications, Research and Development FDA, Novartis, acute myeloid leukaemia
Novartis’ PKC412 (midostaurin) has become the latest in a sequence of FDA Breakthrough Therapy designations awarded this week- bagging the …
More evidence required for Alexion’s Kanuma, says NICE
February 18, 2016Medical Communications, Research and Development Alexion, Kanuma, LAL-D, rare diseases
NICE says it needs additional trial data before it can recommend Alexion’s enzyme replacement therapy Kanuma (sebelipase alfa) for the …
Give GPs feedback on prescribing habits to reduce antibiotic use, says study
February 18, 2016Medical Communications, Research and Development antimicrobial resistance
A trial of more than 1,500 GP practices has shown that sending general practitioners (GPs) letters giving feedback on their …
FDA approves Gilead’s Harvoni in two new indications
February 18, 2016Research and Development Gilead Sciences, MSD, harvoni, hepatitis C
The hepatitis C treatment battle had its latest development yesterday, with the FDA awarding Gilead Science’s market-leading drug Harvoni (ledipasvir/sofosbuvir) …
AZ’s durvalumab awarded breakthrough status in bladder cancer
February 18, 2016Research and Development AstraZeneca, FDA, bladder cancer
AstraZeneca, and its biologics/R&D arm MedImmune, have won FDA Breakthrough Therapy status for their bladder cancer drug durvalumab (MEDI4736), which …
MPS appoints global marketing leader
February 17, 2016Manufacturing and Production
Multi Packaging Solutions International, a global leader in value-added print and packaging solutions for the branded consumer, healthcare and multi-media …
Latest content
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
